Theralase Technologies Inc.
TLT.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 150.08% | -78.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 150.08% | -78.34% | |||
| Cost of Revenue | 34.62% | -48.38% | |||
| Gross Profit | 822.58% | -95.05% | |||
| SG&A Expenses | -14.92% | 13.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.49% | 15.27% | |||
| Operating Income | 31.99% | -56.76% | |||
| Income Before Tax | 32.87% | -56.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.87% | -56.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.87% | -56.29% | |||
| EBIT | 31.99% | -56.76% | |||
| EBITDA | 32.76% | -60.17% | |||
| EPS Basic | 31.71% | -57.69% | |||
| Normalized Basic EPS | 34.62% | -62.50% | |||
| EPS Diluted | 31.71% | -57.69% | |||
| Normalized Diluted EPS | 34.62% | -62.50% | |||
| Average Basic Shares Outstanding | 0.29% | -3.35% | |||
| Average Diluted Shares Outstanding | 0.29% | -3.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||